BioXcel Therapeutics, Inc. Costs and Expenses
BioXcel Therapeutics, Inc. (BTAI) reported Costs and Expenses of $10.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-13
- BioXcel Therapeutics, Inc. costs and expenses for the quarter ending 2026-06-30 was $10.38M, a 35.04% decline year-over-year.
- BioXcel Therapeutics, Inc. costs and expenses for the quarter ending 2026-03-31 was $10.43M, a 1.58% increase year-over-year.
- BioXcel Therapeutics, Inc. costs and expenses for the quarter ending 2025-12-31 was $10.54M, a 2.96% decline year-over-year.
- BioXcel Therapeutics, Inc. costs and expenses for the quarter ending 2025-09-30 was $14.33M, a 7.62% decline year-over-year.
- BioXcel Therapeutics, Inc. costs and expenses for fiscal 2025 was $51.10M, a 26.48% decline from fiscal 2024.
- BioXcel Therapeutics, Inc. costs and expenses for fiscal 2024 was $69.51M, a 59.86% decline from fiscal 2023.
- BioXcel Therapeutics, Inc. costs and expenses for fiscal 2023 was $173.16M, a 8.21% increase from fiscal 2022.
- BioXcel Therapeutics, Inc. costs and expenses for fiscal 2022 was $160.02M, a 49.64% increase from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.38M 10-Q · filed 2026-08-13 | $20.80M 10-Q · filed 2026-08-13 | $31.34M derived: sum of 3 quarters · filed 2026-08-13 | $45.67M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $10.43M 10-Q · filed 2026-05-15 | $20.97M derived: sum of 2 quarters · filed 2026-05-15 | $35.29M derived: sum of 3 quarters · filed 2026-05-15 | $51.27M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $10.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $24.86M derived: sum of 2 quarters · filed 2026-03-27 | $40.84M derived: sum of 3 quarters · filed 2026-08-13 | $51.10M 10-K · filed 2026-03-27 |
| 2025-09-30 | $14.33M 10-Q · filed 2025-11-12 | $30.30M derived: sum of 2 quarters · filed 2026-08-13 | $40.56M 10-Q · filed 2025-11-12 | $51.42M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $15.97M 10-Q · filed 2026-08-13 | $26.24M 10-Q · filed 2026-08-13 | $37.10M derived: sum of 3 quarters · filed 2026-08-13 | $52.60M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $10.27M 10-Q · filed 2026-05-15 | $21.13M derived: sum of 2 quarters · filed 2026-05-15 | $36.63M derived: sum of 3 quarters · filed 2026-05-15 | $55.03M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $10.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $26.37M derived: sum of 2 quarters · filed 2026-03-27 | $44.77M derived: sum of 3 quarters · filed 2026-03-27 | $69.51M 10-K · filed 2026-03-27 |
| 2024-09-30 | $15.51M 10-Q · filed 2025-11-12 | $33.91M derived: sum of 2 quarters · filed 2025-11-12 | $58.65M 10-Q · filed 2025-11-12 | $78.90M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $18.40M 10-Q · filed 2025-08-12 | $43.15M 10-Q · filed 2025-08-12 | $63.40M derived: sum of 3 quarters · filed 2025-08-12 | $112.03M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $24.75M 10-Q · filed 2025-05-12 | $45.00M derived: sum of 2 quarters · filed 2025-05-12 | $93.63M derived: sum of 3 quarters · filed 2025-05-12 | $146.50M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $20.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $68.89M derived: sum of 2 quarters · filed 2025-03-28 | $121.76M derived: sum of 3 quarters · filed 2025-03-28 | $173.16M 10-K · filed 2025-03-28 |
| 2023-09-30 | $48.64M 10-Q · filed 2024-11-14 | $101.51M derived: sum of 2 quarters · filed 2024-11-14 | $152.91M 10-Q · filed 2024-11-14 | $206.04M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $52.87M 10-Q · filed 2024-08-06 | $104.27M 10-Q · filed 2024-08-06 | $157.41M derived: sum of 3 quarters · filed 2024-08-06 | $196.53M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $51.40M 10-Q · filed 2024-05-09 | $104.54M derived: sum of 2 quarters · filed 2024-05-09 | $143.66M derived: sum of 3 quarters · filed 2024-05-09 | $179.95M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $53.13M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $92.26M derived: sum of 2 quarters · filed 2024-03-22 | $128.55M derived: sum of 3 quarters · filed 2024-03-22 | $160.02M 10-K · filed 2024-03-22 |
| 2022-09-30 | $39.13M 10-Q · filed 2023-11-14 | $75.42M derived: sum of 2 quarters · filed 2023-11-14 | $106.89M 10-Q · filed 2023-11-14 | $133.03M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $36.29M 10-Q · filed 2023-08-14 | $67.77M 10-Q · filed 2023-08-14 | $93.90M derived: sum of 3 quarters · filed 2023-08-14 | $120.71M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $31.48M 10-Q · filed 2023-05-09 | $57.61M derived: sum of 2 quarters · filed 2023-05-09 | $84.42M derived: sum of 3 quarters · filed 2023-05-09 | |
| 2021-12-31 | $26.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $52.94M derived: sum of 2 quarters · filed 2023-03-16 | $106.94M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $26.81M 10-Q · filed 2022-11-14 | $80.80M 10-Q · filed 2022-11-14 | ||
| 2018-03-31 | $4.29M 10-Q · filed 2018-05-14 | |||
| 2017-03-31 | $529.00K 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |